AstraZeneca (LSE:AZN) recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important milestone for easier access to vaccinations in 34 U.S. states. This initiative likely contributed to its stock price increase of 12% last quarter,

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for a look at AZN earnings and prospects.

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it’s already announced before.

AstraZeneca is making flu protection more convenient with the launch of an at-home delivery option for FluMist, its nasal spray flu vaccine, the company announced Friday. On the market since 2003, FluMist was previously only available at pharmacies or doctors' offices.

FluMist has been approved since 2003, but, until last year, only for administration by a healthcare practitioner. The new nod allows adults up to 49 years old to use the nasal spray themselves, while parents and caregivers can give it to children aged 2 to 17.

He said about Britain that the firm needed “to see that there is access and a reason to invest.” This is partly a negotiating tactic to get a better deal from the British government, including on what the NHS pays for its drugs.

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s Fasenra (benralizumab) for use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to district court for further proceedings.